Contact   |   Home   |   
 
 
 
Print

Management Team

The Adamas team is comprised of experienced industry veterans with a history of therapeutic innovation and a track record of commercial success.

Gregory Went, Ph.D.,
Chief Executive Officer & Chairman
Dr. Went, founding CEO and Chairman of Adamas Pharmaceuticals, has overseen the development of the company since its inception. Previously, Dr. Went co-founded CuraGen Corporation in 1992, where he served as an Executive Vice President and Director. Dr. Went serves on the Board of Directors of Tethys Bioscience and Angelica Therapeutics and is a Managing Director of Halteres Associates. Dr. Went received his Ph.D. in Chemical Engineering from the University of California, Berkeley, and is the author of 20 papers and an inventor on more than 45 patents and patent applications.

Back to top »

Deborah Foy,
VP Finance and Administration
Deborah Foy brings more than 25 years of finance experience to her position as Vice President, Finance and Administration at Adamas. Her distinguished career includes financial leadership positions in a varietiy of start up manufacturing and biotechnology companies including, Miraibio, Inc., a Hitachi Software Company, Genetrace Systems Inc., as well as Chiron Corporation and Ciba Corning Diagnostics. She began her career in the banking industry. Ms. Foy earned a B.S. in Business Administration at George Mason University.

Back to top »

Gans Ganapati,
VP Corporate Development; General Manager, Adamas India
Mr. Ganapati joined Adamas in January 2007. Mr. Ganapati was the founding CEO of Triesta Sciences and led the company's business prior to its acquisition by HCG Enterprises in 2005. Prior to founding Triesta, Mr. Ganapati was a Vice President in the Technology Group of Credit Suisse First Boston where he advised leading life sciences and technology companies on several landmark transactions. From 1990 to 1994, he was a Project Executive at Tata Industries Limited in India where he was responsible for establishing new ventures in the life sciences arena. Mr. Ganapati received his B Tech from the Indian Institute of Technology, Madras, his PGDM from the Indian Institute of Management, Ahmedabad and his MBA from the Wharton School of the University of Pennsylvania.

Back to top »

Peter Hadrovic, J.D.,
SVP Corporate Development
Mr. Peter Hadrovic joined Adamas Pharmaceuticals in 2008. Before joining Adamas, he was Vice President, Business Development, General Counsel and General Manager of Laserscope, a publically traded medical device company acquired by American Medical Systems. Previously, Mr. Hadrovic specialized in corporate and securities law at Heller Ehrman/Venture Law Group. He also brings valuable expertise from the public sector, where he served as a congressional aide responsible for health care policy, among other issues. Mr. Hadrovic received an A.B. from Princeton University in 1988 and a J.D. from Cornell Law School in 1997.

Back to top »

Ashok Katdare, Ph.D.,
VP Pharmaceutical Development
Dr. Ashok Katdare joined the company in November 2005 and is a Research and Development executive with more than 25 years of experience. Over the course of his career, he has contributed to more than 25 successful New Drug Applications. He joined Adamas from Morton Grove Pharmaceuticals USA, where he was the Vice President for Pharmaceutical R&D. Previously, Dr. Katdare held various research and development positions with Merck Research Laboratories, Delsys Corporation, and Abbott Laboratories. Dr. Katdare holds a Ph.D. in Pharmaceutical Sciences from the University of Michigan, and a Master in Pharmacy from Bombay University. He serves as an expert for the United States Pharmacopeia and has recently published a book on selection of excipients for pharmaceutical and biopharmaceutical dosage forms.

Back to top »

Natalie McClure, Ph.D.,
VP Regulatory Affairs
Dr. McClure brings more than 30 years in pharmaceutical development with more than 20 years of regulatory affairs experience from the pharmaceutical and biotechnology industries, where she has been instrumental in the success of numerous NDAs, MAAs, and INDs. Dr. McClure's professional experience includes leadership positions at Cerimon Pharmaceuticals, Amgen SF LLC., Tularik, Intrabiotics Pharmaceuticals, Matrix Pharmaceuticals and Syntex Research. Dr. McClure is an active industry speaker on regulatory topics including industry/agency communications, clinical trial design and drug products quality. Dr. McClure earned her Ph.D. in Organic Chemistry from Stanford University and a B.S. in Chemistry from the University of Michigan.

Back to top »

Anie K. Roche, J.D., Ph.D.,
VP Intellectual Property
Dr. Anie Roche joined Adamas in 2009 as Vice President of Intellectual Property from Wilson Sonsini Goodrich & Rosati, where she was a Partner at the firm. Previously she was an Associate at Cooley Godward L.L.P. Dr. Roche's expertise includes the strategic development and management of patent portfolios, patent litigation, and licensing for the pharmaceuticals, biotechnology, and bioinformatics industries. From 1991 to 1999, Dr. Roche was a Research Assistant at the University of Minnesota, where she worked in the Department of Cell Biology and Neuroanatomy, and the Department of Pharmacology. Dr. Roche earned her J.D. from the University of Minnesota Law School; her Ph.D. from the University of Minnesota, Department of Pharmacology; and her Bachelors in Pharmacy from the University of Bombay, Bombay, India.

Back to top »

Gayatri Sathyan, Ph.D.,
VP, Clinical Pharmacology
Dr. Gayatri Sathyan joined Adamas in January 2009 after working at ALZA Corporation for 14 years, including 9 years in leadership roles with increasing responsibility. At ALZA she was responsible for leading the clinical pharmacology activities in the development of drug delivery based products and new molecules. She made significant contributions to the successful regulatory approvals of several oral controlled release and transdermals products, such as Ditropan-XL®, Jurnista®, Invega®, Duragesic®, Ionsys® and Viadur®. Dr. Sathyan earned a Ph.D and M.S. in the Division of Pharmaceutics and Drug Delivery Systems, College of Pharmacy, University of Cincinnati. She is a coauthor of more than 32 papers and holds two patents.

Back to top »

Efraim Shek, Ph.D.,
EVP Research and Development
Dr. Efraim Shek is a research and development executive with 31 years of industry experience. He has contributed to the submission of more than 17 successful New Drug Applications to the U.S. Food and Drug Administration (FDA). Dr. Shek joined Adamas Pharmaceuticals in 2005 from Taro Pharmaceuticals USA, where he was the Group Vice President for Pharmaceutical R&D. Previously, Dr. Shek held various research and development positions with Syntex Corporation, Pharmatec, Cephalon, Abbott Laboratories, and a faculty position at the College of Pharmacy, University of Florida, at Gainesville. Dr Shek holds a Ph.D. and M.Sc. degrees in Pharmaceutical Chemistry from University of Kansas, and a Master in Pharmacy from Hebrew University, Israel.

Back to top »

 
 
About Adamas | Advantaged Therapeutics | Resource Center | Newsroom | Careers
© 2010 Adamas Pharmaceuticals, Inc. Privacy Statement | Terms of Use | Site Users Guide